Guardant Health vs Natera
GH and NTRA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GH and NTRA compare
Natera is the larger company, worth 2.3 times as much as Guardant Health ($46.0B against $20.4B).
Guardant Health grew revenue faster over the last twelve months (41.7% versus 37.4% for Natera).
Natera keeps more of each dollar of sales as profit, with a net margin of −5.7% compared with −37.9% at Guardant Health.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GH | NTRA |
|---|---|---|
| Size and price | ||
| Market cap | $20.4B | $46.0B |
| Share price | $151.70 | $319.09 |
| Change, 1 year | 55.0% | 52.3% |
| Change, 5 years | 55.5% | 209% |
| Beta (5Y) | 1.62 | 1.38 |
| Employees | 2,506 | 6,140 |
| StockData Score | ||
| Total score | 10 | 10 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 1 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.9× | 15.8× (better) |
| P/B | – | 24.6× |
| P/FCF | – | 877× |
| FCF yield | −1.1% | 0.11% (better) |
| Fair value | – | $126.82 |
| Margin of safety | – | −152% |
| Growth | ||
| Revenue growth (TTM) | 41.7% (better) | 37.4% |
| Revenue growth, 5Y average | 27.9% | 42.6% (better) |
| Profitability | ||
| Gross margin | 65.2% | – |
| Operating margin | −39.4% | −9.0% (better) |
| Net margin | −37.9% | −5.7% (better) |
| FCF margin | −18.2% | 1.8% (better) |
| Return on equity | – | −10.6% |
| Return on invested capital | – | −36.0% |
| Financial health | ||
| Debt / equity | – | 0.04 |
| Interest coverage | −96.6× | −70.8× (better) |
| Current ratio | 3.60 (better) | 2.81 |
| Altman Z-score | 3.58 | 31.11 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.8% | 95.2% |
| Held by insiders | 1.8% | 3.9% |
| Insider net buying, 12 months | −$173M (better) | −$341M |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 7.2% | 4.4% |
Go deeper
- GH stock overview
- GH income statement
- GH valuation and score
- NTRA stock overview
- NTRA income statement
- NTRA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.